-
24 Years on Gleevec!
ST. LOUIS On Saturday May 16 a GIST Gathering was held at the Barnes Jewish Hospital complex of the Washington University School of medicine in St. Louis. It was the third such meeting in St. Louis and has GIST patients from neighboring states also attending. At the meeting three long-time Gleevec users met and shared […]
Continue reading -
Adjuvant Imatinib in Europe
The European Commission has appproved adjuvant imatinib in GIST patients with significant risk of recurrence. In March the European Medicines Agency had recommended approval for use of imatinib (Glivec or Gleevec) for adjuvant use (prescription to prevent recurrence after successful surgical resection of primary GIST) for patients with an intermediate or high risk of recurrence. […]
Continue reading -
Sarcoma Bike Tour 2006 Funds Awarded
Sarcoma Bike Tour Funds Awarded In July 2006 , Team GIST Support participated in the Team Sarcoma Bike Tour organized by the Liddy Shriver Sarcoma Initiative. Team GIST Support, pictured below, included Megan Lamb, Rob Lamb, and Jonathan Craig. The goal for Team GIST Support was to raise funds for two young researchers: Dr. Anette […]
Continue reading -
Barbara and Sherri Visit Novartis
Novartis had their "kick off"event on January 30, 2009 to recognize the achievement of the oncology department and to lay the foundation for future success in the new year. Their goal this coming year is "Winning for the Patient". One of their big FDA approvals was for adjuvant Gleevec. The half day meeting was for […]
Continue reading -
IGF signals in GIST
Insulin-related growth factor family: potential role in GIST Several 2008 papers suggest that the insulin-related growth factors and associated receptors may be treatment targets for GISTs, including wild-type adult GISTs as well as pediatric GISTs and Carney Triad. This is exciting because development of drugs relevant to the insulin-related growth factor (IGF) family is already […]
Continue reading -
Sorafenib Is Promising
Sorafenib for GIST At the January 2008 ASCO GI Cancers Symposium, Dr. Nimeiri presented a paper describing the first preliminary results of the ongoing Phase II trial of sorafenib (brand name Nexavar) for gastrointestinal stromal tumor. Title: Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): A […]
Continue reading -
Team GIST Completes Sarcoma Tour 2006
Day 1: Arrival at Legoland (July 1st, 2006) Our first full day in Denmark was largely occupied by travel and logistics. We took a train from Copenhagen to Vejle where we first met our outstanding bus driver Jens. Also on the bus were Guy and Nigel, a father and son team from New Zealand. It […]
Continue reading -
Vermont Hills “Invaded” by Team Sarcoma
It was not your usual sight…about 50 bicycle riders traversing the hilly terrain of Vermont back in July. Though some might have been tempted, with tongue in cheek, to opine that they must have been some Tour de France riders who made a wrong turn on the outskirts of Paris, they were actually more like […]
Continue reading -
Attending CTOS conference: a whirlwind experience!
Attending CTOS conference: a whirlwind experience! by Barbara Dore I had the chance to represent GSI at CTOS (Connective Tissue Oncology Society), which was held in London November 13 -15th in the Landmark Hotel. The Landmark Hotel is rather a grand red-brick Victorian Railway hotel, built at the terminus of the Grand Central Railway line […]
Continue reading -
CTOS and SARC Meet in London
Barbara Dore’ (a member of GSI’s board and our science committee) attended the CTOS meeting in London November 13-15 on behalf of GIST Support International. This news story highlights some of the new science findings Barbara gleaned at CTOS, which is the world’s premier gathering of sarcoma experts. You can view the program listing at […]
Continue reading